Recent Updates
Recently added Catalysts
NBTX Positive Sentiment Score: 70/100

NANOBIOTIX to Participate in the Jefferies Global Healthcare Investor Conference

Key Takeaway: Nanobiotix, a late-stage biotechnology company, announced its participation in the Jefferies Global Healthcare Investor Conference on June 5, 2025. The event, which will feature a webcast of the presentation, offers the company a platform to discuss its pioneering nanoparticle-based cancer treatments. This participation is expected to enhance Nanobiotix's visibility among potential investors and stakeholders in the healthcare sector.

Conference Participation Details

Jefferies Global Healthcare Conference
Date: November 18, 2025
Time: 11:30 a.m. GMT / 6:30 a.m. ET
Location: London
Format: Fireside Chat

How to Access

Investors and the general public can listen to both sessions live at:

https://investor.viatris.com

Archived versions will be available following the live events for a limited time.

Market Sentiment Analysis

POSITIVE FACTORS

  • Participation in a major healthcare investor conference enhances visibility.
  • Opportunity to showcase innovative nanoparticle-based therapeutic approaches.
  • Company philosophy emphasizes expanding treatment possibilities for patients.

Full Press Release Details

PARIS and CAMBRIDGE, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering nanoparticle-based approaches to expand treatment possibilities for patients with cancer and other major diseases, announced today that Company management will participate in fireside chats at following conference:
Jefferies Global Healthcare Conference
Date: Thursday, June 5, 2025
Time: 3:45 pm EDT / 9:45 pm CEST
Location: New York, NY
Presenters: Bart van Rhijn, Chief Financial & Business Officer of Nanobiotix
Webcast link: Click here
The fireside chats will be webcast live from the events page of the Investors section of the Company’s website. The replay of the webcast will be available following the event.
Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The Company’s philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life.
Incorporated in 2003, Nanobiotix is headquartered in Paris, France and is listed on Euronext Paris since 2012 and on the Nasdaq Global Select Market in New York City since December 2020. The Company has subsidiaries in Cambridge, Massachusetts (United States) amongst other locations.
Nanobiotix is the owner of more than 25 umbrella patents associated with three (3) nanotechnology platforms with applications in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders of the central nervous system.
Nanobiotix
Communications Department Brandon Owens VP, Communications +1 (617) 852-4835 contact@nanobiotix.com Investor Relations Department Ricky Bhajun Director, Investor Relations +33 (0)6 42 05 34 15 investors@nanobiotix.com
Media Relations
France – HARDY Caroline Hardy +33 06 70 33 49 50 carolinehardy@outlook.fr Global – uncapped Becky Lauer +1 (646) 286-0057 uncappednanobiotix@uncappedcommunications.com
2025-05-28 -- NBTX -- Presenting @ Jefferies -- FINAL

Attachments

2025-05-28 -- NBTX -- Presenting @ Jefferies -- FINAL...

Frequently Asked Questions

When will Nanobiotix present at the Jefferies Conference?

Nanobiotix will present on June 5, 2025, at 3:45 pm EDT.

Who will represent Nanobiotix at the conference?

Bart van Rhijn, Chief Financial & Business Officer, will represent Nanobiotix.

Where is Nanobiotix headquartered?

Nanobiotix is headquartered in Paris, France.

What sectors does Nanobiotix's technology target?

Nanobiotix targets oncology, bioavailability, and central nervous system disorders.

How many patents does Nanobiotix own?

Nanobiotix owns more than 25 umbrella patents related to its technologies.

Last updated: May 28, 2025